Acura Pharmaceuticals
ACUR
ACUR was delisted on the 22nd of February, 2017.
22 hedge funds and large institutions have $10.2M invested in Acura Pharmaceuticals in 2015 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 3 closing their positions.
31% more call options, than puts
Call options by funds: $17K | Put options by funds: $13K
5% more capital invested
Capital invested by funds: $9.76M → $10.2M (+$448K)
0% more funds holding
Funds holding: 22 → 22 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$9.72K |
| 2 |
Group One Trading
Chicago,
Illinois
|
+$4.86K |
| 3 |
Walleye Trading
New York
|
+$3.72K |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$3.37K |
| 5 |
Creative Planning
Overland Park,
Kansas
|
+$243 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$115K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$38.3K |
| 3 |
HCM
Highbridge Capital Management
New York
|
-$38.2K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$9.62K |
| 5 |
SIM
Spark Investment Management
New York
|
-$6.87K |
ACUR Hedge Fund Activity: Q4 2015 in Review
22 of the 3,824 institutional investors tracked by Wall St. Rank reported a position in Acura Pharmaceuticals (ACUR) for Q4 2015, worth a combined $10.2M — up 4.6% from $9.76M a quarter earlier.
Fund positioning in ACUR was balanced in Q4 2015: 3 funds opened new positions, 3 closed out, 4 added to existing stakes and 5 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $9.72K. The largest seller was Jacobs Levy Equity Management, exiting entirely with an estimated $115K sold.
- 22 institutional investors held Acura Pharmaceuticals (ACUR) as of Q4 2015, unchanged from Q3 2015.
- Funds reported $10.2M of Acura Pharmaceuticals stock for Q4 2015, up 4.6% quarter-over-quarter.
- 3 funds opened new Acura Pharmaceuticals positions in Q4 2015 and 3 closed out, a net change of 0 holders.
- The largest Acura Pharmaceuticals buyer in Q4 2015 was Renaissance Technologies, an estimated $9.72K added.
- The largest Acura Pharmaceuticals seller in Q4 2015 was Jacobs Levy Equity Management, an estimated $115K sold.
Based on aggregated 13F filings for Q4 2015.